Seroatlas · Human Serome Atlas

VSTM2A

V-set and transmembrane domain-containing protein 2A

Also known as: MGC33530, VSTM2, VTM2A_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8TAG5
Gene: VSTM2A
Ensembl: ENSG00000170419
Chromosome: 7
Canonical length: 236 aa
Protein class: Plasma proteins, Predicted secreted proteins
Secretome location: Secreted in other tissues
Quaternary structure: Homodimer

OverviewNCBI Gene

Predicted to enable identical protein binding activity. Involved in several processes, including positive regulation of brown fat cell differentiation; positive regulation of lipid storage; and positive regulation of white fat cell proliferation. Predicted to be located in extracellular region. Predicted to be active in membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

236 residues, UniProt reviewed canonical sequence.

>Q8TAG5|VSTM2A
     1  MMGIFLVYVG FVFFSVLYVQ QGLSSQAKFT EFPRNVTATE GQNVEMSCAF QSGSASVYLE
    61  IQWWFLRGPE DLDPGAEGAG AQVELLPDRD PDSDGTKIST VKVQGNDISH KLQISKVRKK
   121  DEGLYECRVT DANYGELQEH KAQAYLKVNA NSHARRMQAF EASPMWLQDM KPRKNVSAAI
   181  PSSIHGSANQ RTHSTSSPQV VAKIPKQSPQ SGARIATSHG LSVLLLVCGF VKGALL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against VSTM2A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.49
Highest tissue expression: 32 nTPM

Expression across tissuesHPA

Tissue

cerebral cortex: 32 nTPM
basal ganglia: 24 nTPM
hypothalamus: 19 nTPM
amygdala: 16 nTPM
retina: 13 nTPM
adrenal gland: 9.6 nTPM

Single-cell type

adrenal medulla cells: 32 nCPM
brain inhibitory neurons: 31 nCPM
retinal bipolar cells: 25 nCPM
other brain neurons: 18 nCPM
brain excitatory neurons: 9.4 nCPM
oligodendrocyte progenitor cells: 9.4 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebral cortex: 104 nTPM
hypothalamus: 63 nTPM
basal ganglia: 56 nTPM
white matter: 41 nTPM
amygdala: 40 nTPM
midbrain: 32 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.64
gnomAD pLI: 0.27
gnomAD missense Z: 0.62
DepMap mean gene effect: 0.04
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

identical protein binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads VSTM2A as an antibody target. Whether an autoantibody or antibody against VSTM2A could matter depends on whether native VSTM2A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

VSTM2A is annotated as secreted, so native VSTM2A circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label VSTM2A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...